000298902 001__ 298902
000298902 005__ 20250216015234.0
000298902 0247_ $$2doi$$a10.3238/arztebl.m2024.0193
000298902 0247_ $$2pmid$$apmid:39417369
000298902 0247_ $$2altmetric$$aaltmetric:171242528
000298902 037__ $$aDKFZ-2025-00341
000298902 041__ $$aEnglish
000298902 082__ $$a610
000298902 1001_ $$0P:(DE-He78)3877ae274d0271d6bf311bb46539f013$$aDelecluse, Susanne$$b0$$eFirst author$$udkfz
000298902 245__ $$aOnconephrology: The Significance of Renal Function for the Development, Diagnosis, and Treatment of Cancer.
000298902 260__ $$aKöln$$bDt. Ärzte-Verl.$$c2024
000298902 3367_ $$2DRIVER$$aarticle
000298902 3367_ $$2DataCite$$aOutput Types/Journal article
000298902 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1739453839_2238$$xReview Article
000298902 3367_ $$2BibTeX$$aARTICLE
000298902 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000298902 3367_ $$00$$2EndNote$$aJournal Article
000298902 500__ $$a#EA:D400# / https://di.aerzteblatt.de/int/archive/article/241946
000298902 520__ $$aModern treatment strategies have markedly improved the chances of survival for patients with cancer. As the population ages, cancer is becoming more common, as is chronic kidney disease (CKD). CKD increases the risk of cancer; conversely, cancer treatments can cause CKD.This review is based on publications retrieved by a selective literature search concerning the epidemiology and comorbidities of cancer and kidney diseases, the renal side effects of new anticancer drugs, and the need to consider renal function in cancer treatment.The prevalence of severe CKD in Germany is 2.3%. Persons who have CKD, are on dialysis, or have undergone kidney transplantation are 1.2 to 3.5 times more likely to develop cancer than the general population. For patients who have CKD or are dialysis-dependent, the doses of approximately 67% of anticancer drugs need to be adjusted on the basis of their glomerular filtration rate and the renally excreted fraction of the drug. The optimal efficacy of therapeutic drugs, as well as of those used for diagnostic purposes, and the minimization of side effects, depend critically on adapted dosing and on proper timing of administration before or after dialysis. Modern anticancer drugs can also cause acute kidney damage (incidence with checkpoint inhibitors: 2-16%).Patients who have CKD, are on dialysis, or have undergone kidney transplantation make up a considerable fraction of persons being treated for cancer, and they need interdisciplinary treatment.
000298902 536__ $$0G:(DE-HGF)POF4-314$$a314 - Immunologie und Krebs (POF4-314)$$cPOF4-314$$fPOF IV$$x0
000298902 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000298902 650_7 $$2NLM Chemicals$$aAntineoplastic Agents
000298902 650_2 $$2MeSH$$aHumans
000298902 650_2 $$2MeSH$$aNeoplasms: complications
000298902 650_2 $$2MeSH$$aNeoplasms: therapy
000298902 650_2 $$2MeSH$$aRenal Insufficiency, Chronic: therapy
000298902 650_2 $$2MeSH$$aRenal Insufficiency, Chronic: complications
000298902 650_2 $$2MeSH$$aRenal Insufficiency, Chronic: diagnosis
000298902 650_2 $$2MeSH$$aRenal Insufficiency, Chronic: physiopathology
000298902 650_2 $$2MeSH$$aAntineoplastic Agents: adverse effects
000298902 650_2 $$2MeSH$$aGermany: epidemiology
000298902 650_2 $$2MeSH$$aGlomerular Filtration Rate
000298902 650_2 $$2MeSH$$aKidney Transplantation
000298902 650_2 $$2MeSH$$aRenal Dialysis
000298902 650_2 $$2MeSH$$aPrevalence
000298902 7001_ $$aHarder, Fridtjof$$b1
000298902 7001_ $$aKeller, Frieder$$b2
000298902 7001_ $$aZeier, Martin$$b3
000298902 7001_ $$aZschäbitz, Stefanie$$b4
000298902 773__ $$0PERI:(DE-600)2406159-1$$a10.3238/arztebl.m2024.0193$$gVol. 121, no. 24$$n24$$p793-799$$tDeutsches Ärzteblatt international$$v121$$x1866-0452$$y2024
000298902 909CO $$ooai:inrepo02.dkfz.de:298902$$pVDB
000298902 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)3877ae274d0271d6bf311bb46539f013$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000298902 9131_ $$0G:(DE-HGF)POF4-314$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vImmunologie und Krebs$$x0
000298902 9141_ $$y2024
000298902 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bDTSCH ARZTEBL INT : 2022$$d2025-01-07
000298902 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2025-01-07
000298902 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2025-01-07
000298902 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2025-01-07
000298902 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2025-01-07
000298902 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2025-01-07
000298902 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2025-01-07
000298902 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bDTSCH ARZTEBL INT : 2022$$d2025-01-07
000298902 9201_ $$0I:(DE-He78)D400-20160331$$kD400$$lPathologie infektionsbedingter Tumoren$$x0
000298902 9200_ $$0I:(DE-He78)D400-20160331$$kD400$$lPathologie infektionsbedingter Tumoren$$x0
000298902 980__ $$ajournal
000298902 980__ $$aVDB
000298902 980__ $$aI:(DE-He78)D400-20160331
000298902 980__ $$aUNRESTRICTED